58 related articles for article (PubMed ID: 28349781)
1. Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data.
Ye SL; Chen X; Yang J; Bie P; Zhang S; Liu F; Liu L; Zhou J; Dou K; Yip CS; Yang X
Tumour Biol; 2017 Mar; 39(3):1010428317695030. PubMed ID: 28349781
[TBL] [Abstract][Full Text] [Related]
2. Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges.
Jiang JF; Lao YC; Yuan BH; Yin J; Liu X; Chen L; Zhong JH
Oncotarget; 2017 May; 8(20):33911-33921. PubMed ID: 28430610
[TBL] [Abstract][Full Text] [Related]
3. Patients with hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation: A meta-analysis.
Liu J; Qian J; Yang Z; Zhou L; Zheng S
J Hepatol; 2024 May; 80(5):e219-e221. PubMed ID: 37939856
[No Abstract] [Full Text] [Related]
4. Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis.
Tsai HM; Han MZ; Lin YJ; Chang TT; Chen CY; Cheng PN; Chuang CH; Wu IC; Chen PJ; Kang JW; Chiu YC; Chiu HC; Chien SC; Kuo HY
Cancer Immunol Immunother; 2021 Jul; 70(7):1929-1937. PubMed ID: 33409737
[TBL] [Abstract][Full Text] [Related]
5. Reply to: "Patients with hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation: A meta-analysis".
Soin A; Lesurtel M; Clavien PA
J Hepatol; 2024 May; 80(5):e222. PubMed ID: 38340810
[No Abstract] [Full Text] [Related]
6. Re-188 lipiodol in hepatocellular carcinoma with portal vein thrombosis: a pilot study using novel chelating agent N-DEDC and its comparison with (A)HDD.
Datta Gupta SS; Shamim SA; Gamanagatti S; Gupta P; Khan MA; Mallia MB; Chirayil V; Dash A; Bal C
Nucl Med Commun; 2024 Jun; 45(6):510-518. PubMed ID: 38632971
[TBL] [Abstract][Full Text] [Related]
7. Portal Vein Thrombosis After Transarterial Embolization for Hepatocellular Carcinoma.
Schwab ME; Decker HC; Monto A; Sawhney R; Corvera CU
JAMA Surg; 2024 Mar; 159(3):345-347. PubMed ID: 38150246
[TBL] [Abstract][Full Text] [Related]
8. Prolonged response to Tyrosine Kinase Inhibitors followed by Immunotherapy in metastatic hepatocellular carcinoma: A rare case report.
Roy P; Parthasarathy KM
J Cancer Res Ther; 2023; 19(5):1457-1461. PubMed ID: 37787330
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib-induced interstitial pneumonitis in a patient with hepatocellular carcinoma: a case report.
Myung HJ; Jeong SH; Kim JW; Kim HS; Jang JH; Yoon HI; Kim JS
Gut Liver; 2010 Dec; 4(4):543-6. PubMed ID: 21253306
[TBL] [Abstract][Full Text] [Related]
10. Retraction Note: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.
Oya M; Kaneko S; Imai T; Tsujino T; Sunaya T; Okayama Y
Cancer Chemother Pharmacol; 2024 May; 93(5):523. PubMed ID: 37715787
[No Abstract] [Full Text] [Related]
11. Current Status of Sorafenib Use for Treatment of Hepatocellular Carcinoma.
El-Serag HB; Margaret M; Alkek AB
Gastroenterol Hepatol (N Y); 2017 Oct; 13(10):623-625. PubMed ID: 29230141
[No Abstract] [Full Text] [Related]
12. Timely diagnosis and intervention in a case of portal vein thrombosis: A life saved!
Singh P; Ambulkar R; Gupta A; Maji M
J Anaesthesiol Clin Pharmacol; 2022; 38(4):690-691. PubMed ID: 36778812
[No Abstract] [Full Text] [Related]
13. Glioblastoma multiforme in conus medullaris with intracranial metastasis after postoperative adjuvant therapy.
Yan C; Kong X; Yin H; Wang Y; He H; Zhang H; Gao J; Li Y; Ma W
Medicine (Baltimore); 2017 Mar; 96(13):e6500. PubMed ID: 28353599
[TBL] [Abstract][Full Text] [Related]
14. TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.
Ye S; Zhao XY; Hu XG; Li T; Xu QR; Yang HM; Huang DS; Yang L
Oncol Rep; 2017 Apr; 37(4):2215-2226. PubMed ID: 28350084
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence.
Liao Y; Zheng Y; He W; Li Q; Shen J; Hong J; Zou R; Qiu J; Li B; Yuan Y
Oncol Lett; 2017 Feb; 13(2):984-992. PubMed ID: 28356989
[TBL] [Abstract][Full Text] [Related]
16. 2-Deoxyglucose and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells.
Tomizawa M; Shinozaki F; Motoyoshi Y; Sugiyama T; Yamamoto S; Ishige N
Oncol Lett; 2017 Feb; 13(2):800-804. PubMed ID: 28356961
[TBL] [Abstract][Full Text] [Related]
17. A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors.
Kim GM; Reid T; Shin SJ; Rha SY; Ahn JB; Lee SS; Chung HC
Invest New Drugs; 2017 Dec; 35(6):773-781. PubMed ID: 28353123
[TBL] [Abstract][Full Text] [Related]
18. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Finn RS; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Xu DZ; Hernandez S; Liu J; Huang C; Mulla S; Wang Y; Lim HY; Zhu AX; Cheng AL;
N Engl J Med; 2020 May; 382(20):1894-1905. PubMed ID: 32402160
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
